Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ASP 6537

Known as: ASP-6537, ASP6537 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Additive antithrombotic effect of ASP6537, a selective cyclooxygenase (COX)‐1 inhibitor, in combination with clopidogrel in guinea pigs
ABSTRACT Clopidogrel (Plavix®, Sanofi‐Aventis), the adenosine diphosphate P2Y12 receptor antagonist, is reported to be effective… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
2017
2017
Inhibitory effects of ASP6537, a selective cyclooxygenase-1 inhibitor, on thrombosis and neointima formation in rats.
INTRODUCTION Percutaneous coronary interventions (PCIs), such as balloon angioplasty and stent placement, are effective in the… Expand
2013
2013
ASP6537, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without "aspirin dilemma".
INTRODUCTION Aspirin inhibits both the cyclooxygenase (COX)-1-dependent production of thromboxane A2 (TXA2) in platelets and COX… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE